Stomach Cancer Industry Insights: Market Forecast to 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Was The Stomach Cancer Market Worth In 2025, And What Is Its Anticipated Value By 2029?

The stomach cancer market has experienced rapid expansion recently. It is forecast to increase from $3.27 billion in 2024 to $3.74 billion in 2025, achieving a compound annual growth rate (CAGR) of 14.1%. The growth observed in previous periods is linked to a rising prevalence of Helicobacter pylori infection, the ongoing development of targeted therapies, a greater adoption of combination chemotherapy regimens, increased availability of immunotherapy treatments, and evolving lifestyle changes.

The stomach cancer market size is projected to see significant growth in the coming years. It is expected to reach $6.28 billion by 2029, growing at a compound annual growth rate (CAGR) of 13.9%. This expansion during the forecast period can be attributed to a rise in global stomach cancer incidence, increased public and private healthcare spending, a surge in approvals for targeted therapies and biologics, growing interest from pharmaceutical companies in oncology, and an increase in collaborations between research institutions and biotech firms. Major trends anticipated in the forecast period include the integration of companion diagnostics, the incorporation of genomic testing into clinical practice, innovations in immunotherapy combinations, advancements in endoscopic techniques, and the development of microbiome-based therapies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25913&type=smp

Which Industry Drivers Are Expected To Accelerate The Stomach Cancer Market From 2025 To 2029?

An increasing prevalence of Helicobacter pylori infection is projected to propel the expansion of the stomach cancer market in the future. Helicobacter pylori infection refers to a condition caused by the Helicobacter pylori bacteria, which colonizes the stomach lining and can lead to inflammation, ulcers, and an elevated risk of stomach cancer. The growing occurrence of Helicobacter pylori infection is mainly attributed to poor sanitation, which facilitates the fecal-oral and oral-oral transmission of the bacteria in crowded or unhygienic living conditions. Helicobacter pylori infection contributes to stomach cancer by inducing chronic inflammation and cellular damage within the stomach lining, leading to precancerous changes and subsequent tumor development. For instance, in November 2024, the Government of Canada, a Canada-based government agency, reported that the recurrence rate of Helicobacter pylori infection was 19% in 2023, with this rate fluctuating based on factors like geographic location and age group. Thus, the rising prevalence of Helicobacter pylori infection is fueling the growth of the stomach cancer market.

What Are The Different Segment Classifications Within The Stomach Cancer Market?

The stomach cancer market covered in this report is segmented –

1) By Type: Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Other Types

2) By Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery

3) By Route of Administration: Oral, Parenteral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Ambulatory Surgery Centers, Hospitals And Specialty Clinics, Other End-Users

Subsegments:

1) By Adenocarcinoma: Intestinal Type, Diffuse Type

2) By Lymphoma: Mucosa-Associated Lymphoid Tissue Lymphoma, Diffuse Large B-Cell Lymphoma

3) By Gastrointestinal Stromal Tumor: Kit-Positive Gastrointestinal Stromal Tumor, Platelet-Derived Growth Factor Receptor Alpha-mutant Gastrointestinal Stromal, Wild-Type Gastrointestinal Stromal Tumors

4) By Carcinoid Tumor: Typical Carcinoid, Atypical Carcinoid

5) By Other Types: Squamous Cell Carcinoma, Small Cell Carcinoma, Undifferentiated Tumors

What Are The Latest Industry Trends Transforming The Stomach Cancer Market?

Major companies active in the stomach cancer treatment market are prioritizing the development of advanced solutions, including claudin (CLDN18.2)-targeted cytolytic antibody therapy, to improve the precision of first-line treatments for HER2-negative gastric and gastroesophageal junction (GEJ) adenocarcinoma. Claudin (CLDN18.2)-targeted cytolytic antibody therapy employs a monoclonal antibody designed to selectively adhere to CLDN18.2-expressing tumor cells and induce cytotoxic effects when combined with chemotherapy, thereby enhancing both progression-free and overall survival outcomes. For instance, in October 2024, Astellas Pharma US, Inc., a Japan-based pharmaceutical firm, launched Vyloy (zolbetuximab-clzb), a claudin (CLDN18.2)-directed cytolytic antibody for the management of gastric and gastroesophageal junction (GEJ) cancer. This novel biologic therapy is administered intravenously alongside fluoropyrimidine- and platinum-containing chemotherapy, demonstrating a median progression-free survival benefit of up to 10.6 months and overall survival of up to 18.2 months in clinical trials. This therapeutic approach specifically targets CLDN18.2-positive cancer cells, resulting in reduced off-target toxicity and increased treatment specificity, marking a substantial step forward in personalized oncology for advanced gastric cancer.

Which Leading Companies Dominate The Stomach Cancer Market Share?

Major companies operating in the stomach cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck And Co. Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca plc, Novartis Ag, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited., Eli Lilly And Company, Amgen Inc, Mayo Clinic, Daiichi Sankyo Company Limited., Illumina Inc., BeiGene Ltd., Celltrion Healthcare Co. Ltd., Biocon Limited., Guardant Health Inc., Zai Lab Limited., MacroGenics Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/stomach-cancer-global-market-report

Which Region Currently Holds The Largest Share Of The Stomach Cancer Market?

North America was the largest region in the stomach cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stomach cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Stomach Cancer Market Report:

https://www.thebusinessresearchcompany.com/customise?id=25913&type=smp

Browse Through More Reports Similar to the Global Stomach Cancer Market 2025, By The Business Research Company

Gastric Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Esophageal Cancer Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/esophageal-cancer-global-market-report

Gastric Cancer Diagnostic Procedure Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastric-cancer-diagnostic-procedure-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795